Drug Profile
Research programme: antiviral antibody therapy - InNexus/Arana Therapeutics
Latest Information Update: 21 Aug 2009
Price :
$50
*
At a glance
- Originator EvoGenix
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 06 Oct 2006 Preclinical trials in Viral infections in Australia (unspecified route)